Eva Domingo‐Doménech

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2”.

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Advances(2022)10.1182/bloodadvances.2020003971

N/A

1.1DataRank · unranked

40 citations

Steven M. Horwitz, Ranjana H. Advani, Jacob Haaber Christensen, Eva Domingo‐Doménech, Giuseppe Rossi +19 more

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2

N/A

0.282DataRank · unranked

5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024015282

N/A

0.185DataRank · unranked

2 citations

Neha Mehta–Shah, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser +18 more

855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE

Hematological Oncology(2025)10.1002/hon.70096_855

N/A

0DataRank · unranked

0 citations

Eva Domingo‐Doménech, David Sidransky, Ohad S. Bentur, Pier Luigi Zinzani, Kate Cwynarski